Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma

RecruitingOBSERVATIONAL
Enrollment

57

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions
Chronic Rhinosinusitis With Nasal PolypsAsthma
Interventions
DRUG

Mepolizumab 100 MG [Nucala]

subcutaneous injection once a month

Trial Locations (2)

57010

RECRUITING

Pulmonary Clinic of Aristotle University of Thessaloniki, George Papanikolaou Hospital, Thessaloniki

RECRUITING

University Pulmonary Clinic, George Papanikolaou Hospital, Thessaloniki

All Listed Sponsors
collaborator

Department of Otorhinolaryngology, Head and Neck Surgery, George Papanikolaou Hospital

UNKNOWN

collaborator

Department of Otorhinolaryngology, Democritus University of Thrace, Alexandroupolis

UNKNOWN

collaborator

Department of Pulmonology, Democritus University of Thrace, Alexandroupolis

UNKNOWN

collaborator

Respiratory Medicine Department, University of Ioannina, Faculty of Medicine

UNKNOWN

collaborator

Department of Respiratory Medicine, National and Kapodistrian University of Athens

UNKNOWN

collaborator

Department of Allergy and Clinical Immunology, 424 General Military Training Hospital

UNKNOWN

collaborator

Department of Otolaryngology, Head and Neck Surgery, Sotiria General Hospital

UNKNOWN

collaborator

Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens

UNKNOWN

lead

Aristotle University Of Thessaloniki

OTHER